Prasugrel Hydrochloride

cytochrome P450 family 2 subfamily B member 6 ; Homo sapiens







11 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 32974447 Acute thrombosis of everolimus-eluting platinum chromium stent caused by impaired prasugrel metabolism due to cytochrome P450 enzyme 2B6*2 (C64T) polymorphism: a case report. 2020 Aug 1
2 30993551 Inhibitory Effect of Vonoprazan on the Metabolism of [14C]Prasugrel in Human Liver Microsomes. 2019 Oct 1
3 24245489 First report of a subacute stent thrombosis in a prasugrel resistant patient successfully managed with ticagrelor. 2014 1
4 23615745 Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness. 2013 Jul 2
5 28520385 Prasugrel Therapy and CYP Genotype 2012 1
6 21550074 Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients. 2011 Nov 3
7 21053990 Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. 2010 Dec 1
8 19047469 Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. 2009 Mar 3
9 19530977 Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. 2009 Aug 1
10 18094219 Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. 2008 Jan 4
11 19122335 Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. 2008 1